On August 28, 2018 Aurinia Pharmaceuticals Inc., (NASDAQ:AUPH)(TSX:AUP) reported it will be featured as a presenting company at the 20th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC (Press release, Aurinia Pharmaceuticals, AUG 28, 2018, https://ir.auriniapharma.com/news/detail/122/aurinia-announces-participation-at-the-20th-annual-global-investment-conference-in-new-york-city-september-4-6-2018 [SID1234529090]). The conference is being held on September 4-6, 2018 at the St. Regis New York Hotel in New York City.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Celia Economides, Vice President of Corporate and Public Affairs, will provide an overview of the Company’s business on Thursday, September 6 at 10:50am ET.

If you are an institutional investor, and would like to attend the Company’s presentation, please click on the following link (www.rodmanevents.com) to register for the conference. Once your registration is confirmed, you will be prompted to log into the conference website to request a one-on-one meeting with the Company.

The presentation will be webcast live and can be accessed via the investor section of the Aurinia website, www.auriniapharma.com. A replay will also be archived on the site following the event.

On August 28, 2018 VBI Vaccines Inc. (NASDAQ: VBIV) ("VBI"), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, reported that Jeff Baxter, President and CEO, will present a corporate overview at the 20th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC, in New York City on Thursday, September 6, 2018, at 12:05 PM ET (Press release, VBI Vaccines, AUG 28, 2018, View Source [SID1234529430]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation and a subsequent replay may be accessed by visiting the Investors page of VBI’s website at: www.vbivaccines.com/investors/events-presentations/. A replay of the webcast will be archived on the company’s website for 90 days following the presentation.

Event: 20th Annual Rodman & Renshaw Global Investment Conference sponsored by H.C. Wainwright & Co., LLC
Date: Thursday, September 6, 2018
Time: 12:05 – 12:30 p.m. ET
Location: Louis XVI A, St. Regis New York Hotel in New York City
Webcast: View Source

On August 28, 2018 Kiadis Pharma N.V. ("Kiadis Pharma" or the "Company") (Euronext Amsterdam and Brussels: KDS), a clinical-stage biopharmaceutical company developing a patient-specific T-cell product designed to be delivered following a haploidentical hematopoietic stem cell transplant, or HSCT, in order to support the patient’s newly transplanted immune system before it becomes fully functional, reported that it is scheduled to attend the following investor conferences in September 2018 (Press release, Kiadis, AUG 28, 2018, View Source [SID1234529092]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Goldman Sachs 8th Annual Biotech Symposium

September 7, 2018, Goldman Sachs Offices, River Court, 120 Fleet Street, London, UK

Oppenheimer Fall Summit focused on Specialty Pharma and Rare Disease

September 26-27, 2018, The Langham, 400 5th Avenue, New York, USA

KBC Securities 6th Biotech and Healthcare Conference

September 27, 2018, Convene Grand Central, 101 Park Avenue, New York, USA

For more information, please contact:

Kiadis Pharma:

Karl Hård, Head of IR & Communications

Tel. +31 611 096 298

[email protected]

Optimum Strategic Communications:

Mary Clark, Supriya Mathur, Hollie Vile

Tel: +44 203 714 1787

[email protected]

On August 28, 2018 Tocagen Inc. (Nasdaq: TOCA), a clinical-stage, cancer-selective gene therapy company, reported that Marty Duvall, chief executive officer, will participate in a panel discussion titled, "Chinese Capital Meets Western Innovation" on Tuesday, September 4, at 11:20 a.m. Eastern Standard Time, at the B. Riley FBR Annual Healthcare Conference (Press release, Tocagen, AUG 28, 2018, View Source;p=RssLanding&cat=news&id=2365149 [SID1234529155]). In addition, Mr. Duvall will present a corporate overview at the 20th Annual Global Investment Conference sponsored by H.C. Wainwright & Co. on Wednesday, September 5, at 9:35 a.m. Eastern Standard Time, also in New York City.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The live audio webcast from the H.C. Wainwright conference and subsequent replay may be accessed by visiting the "Events & Presentations" page in the investors section of Tocagen’s website. The webcast will be available shortly after conclusion of the presentation and archived on the company’s website for 30 days following the presentation.

On August 28, 2018 Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, reported that data from the Company’s chimeric antigen receptor T-cell (CAR T) adaptor molecule (CAM) platform will be presented at the CAR-TCR Summit 2018 being held from Sept. 4th – 7th, 2018 in Boston, MA (Press release, Endocyte, AUG 28, 2018, View Source [SID1234529171]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Key Presentations and Symposia:
Chris Leamon, Ph.D., vice president of research at Endocyte, will lead a deep-dive workshop on the Company’s CAM-based therapies and their potential to induce an immune response while mitigating or preventing severe cytokine release syndrome.

Title: Bi-specific Adaptor Controlled CAR-T Cell Therapy for Solid and Liquid Tumors
When: Tuesday, Sept. 4, 2018 from 12:00 p.m. – 2:00 p.m. ET
Session Title: Deep Dive Discussion Day: CAR-TCR Discovery Track
Location: Cityview 1 Room (Seaport Hotel & World Trade Center)

Endocyte will also present a poster with new preclinical data from its CAM-based therapy platform.

Poster #: 15
Title: Bispecific Adaptor Molecule Controlled Folate Receptor CAR-T Cell Immunotherapy: In-Vitro Activity and T-cell Exhaustion Studies
When: Thursday, Sept. 6, 2018 from 8:00 a.m. – 9:15 a.m. ET
Session Title: Scientific Poster Session
Location: Commonwealth Hall Salon C, Harbor Level (Seaport Hotel & World Trade Center)

Endocyte will also present two posters containing previously-presented preclinical data from its CAM-based therapy platform.

Poster #: 4
Title: Adaptor Controlled CAR-T Cell Immunotherapy for Treatment of Folate Receptor-Alpha/Beta Positive Solid and Liquid Tumors
When: Thursday, Sept. 6, 2018 from 8:00 a.m. – 9:15 a.m. ET
Session Title: Scientific Poster Session
Location: Commonwealth Hall Salon C, Harbor Level (Seaport Hotel & World Trade Center)

Poster #: 5
Title: Regulation of CAR-T Cell Therapy in Real-Time Using Bispecific Small Molecule Adaptors in Monospecific Competitors
When: Thursday, Sept. 6, 2018 from 8:00 a.m. – 9:15 a.m. ET
Session Title: Scientific Poster Session
Location: Commonwealth Hall Salon C, Harbor Level (Seaport Hotel & World Trade Center)

Website Information:
Endocyte routinely posts important information intended for investors on its website, www.endocyte.com, in the "Investors & News" section. Endocyte uses this website as a means of disclosing material information in legal compliance with its disclosure obligations under Regulation FD. Accordingly, investors should monitor the "Investors & News" section of Endocyte’s website, in addition to following the company’s press releases, SEC filings, public conference calls, presentations and webcasts. The information contained on, or that may be accessed through, the Endocyte website is not incorporated by reference into, and is not a part of, this document.